COMPARATIVE CHARACTERISTICS OF MORPHOMETRIC PARAMETRS OF SINUSOIDAL HEMOCAPILLARIES OF THE LIVER AFTER 2 AND 4 WEEKS OF EXPERIMENTAL EXPOSURE TO 10% CANNABIDIOL OIL
DOI:
https://doi.org/10.32689/2663-0672-2025-1-13Keywords:
Cannabidiol, CBD, rats, liver, sinusoids, histology, morphometryAbstract
Introduction. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid found in Cannabis sativa, the popularity, use and availability of which is growing worldwide. CBD has been shown to be therapeutically effective in treating severe epileptic diseases in children, and is also used to treat pain, anxiety, and depression, among other things. However, there is evidence in the literature of side effects and hepatotoxicity associated with the use of CBD. Additional experimental and clinical studies are needed to determine the nature and severity of liver damage, including vascular damage, and hemodynamic features, particularly at the level of the capillary network. The purpose of the study: to determine the features of the morphological organization and morphometric parameters of sinusoidal hemocapillaries of the liver after 2 and 4 weeks of experimental exposure to 10% Cannabidiol oil. Methodology: The material for morphological research was the liver tissue of rats of the control and experimental groups. The experimental group was divided into 2 series of rats with different terms of exposure to 10% cannabidiol oil. Rats of the first series (14 individuals) were given orally dripped 10% cannabidiol oil at a dose of 10 mg/kg/day once a day for 2 weeks, rats of the second series (14 individuals) were given orally dripped 10% cannabidiol oil at a dose of 10 mg/kg/day once a day for 4 weeks. The experiments were conducted in accordance with the provisions of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Strasbourg, 1986), Council of Europe Directive 2010/63/EU, Law of Ukraine No. 3447-IV “On the Protection of Animals from Cruelty to Animals”. To objectify the results of the study, a morphometric method was used to determine the diameters of sinusoidal hemocapillaries of the liver of rats of the control and experimental groups of both series using the Aperio ImageScope v12.3.3 software (Leica biosystems, Wetzlar, Germany). Statistical calculations were performed. The difference was considered statistically significant at a minimum significance level of p<0.05. Scientific novelty. The microscopic organization of the liver lobule was preserved and did not undergo histopathological changes under the conditions of experimental exposure to 10% CBD oil (10 mg/kg/day) as a dietary supplement for two and four weeks. The average diameter of the sinusoids in both series of the experimental group did not differ significantly from the control (p>0.05) and did not differ in dynamics (p>0.05). Diagnosed single dilated and hyperemic sinusoids in two series of the experimental group, respectively in 21.43% and 28.57% did not differ from the control group (20%) (p>0.05). Conclusions. The results of morphological and morphometric analysis of liver sinusoids after two and four weeks of experimental exposure to CBD indicate the safety of using a 10% CBD oil at a dose of 10 mg/kg/day.
References
Шевчук М. М., Волос Л. І. Терапевтичний потенціал канабідіолу: найважливіші здобутки на шляху до нової ери. Медична наука України. 2023. 19(2), 132–141. https://doi.org/10.32345/2664-4738.2.2023.17
Ben-Menachem E., Gunning B., Arenas Cabrera C. M., VanLandingham K., Crockett J., Critchley D., et al. A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. CNS Drugs. 2020. 34(6), 661–72. https://doi.org/10.1007/s40263-020-00726-4
Bhamra S. K., Desai A., Imani-Berendjestanki P., Horgan M. The emerging role of cannabidiol (CBD) products; a survey exploring the public's use and perceptions of CBD. Phytother Res. 2021. 35(10), 5734–40. https://doi.org/10.1002/ptr.7232
Chesney E., Oliver D., Green A., Sovi S., Wilson J., Englund A., Freeman T. P., McGuire P. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020 Oct. 45(11), 1799–1806. doi: 10.1038/s41386-020-0667-2.
Ciura K., Jarzyńska K., Greber K. E., Sawicki W., Jagiello K., Wielgomas B, Kierkowicz M. Is the potential for bioaccumulation of cannabinoids underestimated? Insights from biomimetic chromatography in cannabinoid exposure evaluation. Food Chem Toxicol. 2025 Mar; 197, 115252. doi: 10.1016/j.fct.2025.115252.
Corroon J., Phillips J. A. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018 Jul 1. 3(1), 152–161. doi: 10.1089/can.2018.0006.
Crippa JAS., Zuardi A. W., Guimarães F. S., et al. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw. Open 2021. Aug 2; 4(8), e2120603. doi: 10.1001/jamanetworkopen.2021.20603.
Devinsky O., Kraft K., Rusch L., Fein M., Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study. J Pharm Sci. 2021 Dec. 110(12), 3946-3952. doi: 10.1016/j.xphs.2021.08.012
Devinsky O., Cross J. H., Laux L., Marsh E., Miller I., Nabbout R., et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017. 376(21), 2011–20. https://doi.org/10.1056/NEJMoa1611618
Devinsky O., Patel A. D., Cross J. H., Villanueva V., Wirrell E. C., Privitera M., et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018. 378(20), 1888–97. https://doi.org/10.1056/NEJMoa1714631
Devinsky O., Patel A. D., Thiele E. A., Wong M. H., Appleton R., Harden C. L., et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018. 90(14), e1204–11. https://doi.org/10.1212/WNL.0000000000005254
Dos Santos R. G., Guimarães F. S., Crippa JAS., Hallak JEC., Rossi G. N., Rocha J. M., Zuardi A. W. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin Drug Metab Toxicol. 2020 Jun. 16(6), 517–526. doi: 10.1080/17425255.2020.1754793
Forbes Health [Internet]. 2024 [cited 2024 Jun 7]. CBD statistics, data and use (2024). Available from: https://www.forbes.com/health/cbd/cbd-statistics
Goodman S., Wadsworth E., Leos-Toro C., Hammond D. International Cannabis Policy Study team. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy. 2020 Feb. 76, 102658. doi: 10. 1016/j.drugpo.2019.102658.
Goodman S., Wadsworth E., Schauer G., Hammond D. Use and Perceptions of Cannabidiol Products in Canada and in the United States. Cannabis Cannabinoid Res. 2022 Jun. 7(3), 355–364. doi: 10.1089/can.2020.0093.
Hosseini A., McLachlan A. J., Lickliter J. D. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2021 Apr. 87(4), 2070–2077. doi: 10.1111/bcp.14617.
https://www.navs.edu.ua/files/zakon_ukr/2021/nov1_120421.pdf
Leehey M. A., Liu Y., Hart F., Epstein C., Cook M., Sillau S., et al. Safety and tolerability of cannabidiol in Parkinson disease: an open label, dose-escalation study. Cannabis Cannabinoid Res. 2020. 5(4), 326–36. https://doi.org/10.1089/can.2019.0068
Lo L. A., Christiansen A., Eadie L., Strickland J. C., Kim D. D., Boivin M., Barr A. M., MacCallum C. A. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023 Jun. 293(6), 724–752. https://doi.org/10.1111/joim.13627
Lopez H. L., Cesareo K. R., Raub B., Kedia A. W., Sandrock J. E., Kerksick C. M., Ziegenfuss T. N. Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects. J Diet Suppl. 2020. 17(5), 561–586. doi: 10.1080/19390211.2020.1765941.
Morrison G., Crockett J., Blakey G., Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Nov. 8(8), 1009–1031. doi: 10.1002/cpdd.665.
Taylor L., Crockett J., Tayo B., Checketts D., Sommerville K.. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 2020 Mar;104(Pt A):106938. doi: 10.1016/j.yebeh.2020.106938.
Thiele E. A., Marsh E. D., French J. A., Mazurkiewicz-Beldzinska M., Benbadis S. R., Joshi C., et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018. 391(10125), 1085–96. https://doi.org/10.1016/S0140-6736(18)30136-3
Vlad R. A., Hancu G., Ciurba A., Antonoaea P., Rédai E. M., Todoran N., Silasi O., Muntean D. L. Cannabidiol - therapeutic and legal aspects. Pharmazie. 2020 Oct 1. 75(10), 463-69. https://doi.org/10.1691/ph.2020.0076
Watkins P. B., Church R. J., Li J., Knappertz V. Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase I clinical trial. Clin Pharmacol Ther. 2021. 109(5), 1224–31. https://doi.org/10.1002/cpt.2071
Williamson E. M., Liu X., Izzo A. A. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. Br J Pharmacol. 2020. 177(6), 1227–40. https://doi.org/10.1111/bph.14943
Wilson-Poe A. R., Smith T., Elliott M. R., Kruger D. J., Boehnke K. F. Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults. JAMA Netw Open. 2023 Dec 1. 6(12), e2347373. doi: 10.1001/jamanetworkopen.2023.47373.